This article is more than 5 years old. Information may no longer be current.

Macugen receives approval in Europe

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — A treatment for neovascular age-related macular degeneration has received a positive opinion from European authorities, according to the drug’s marketer.

Macugen (pegaptanib, Pfizer/Eyetech) will be marketed in Europe exclusively by Pfizer once the European Commission grants marketing authorization, the company said in a press release. Pfizer expects final approval to be granted by the end of the year.

Macugen targets vascular endothelial growth factor, a protein proven to act as a signal in triggering abnormal blood vessel growth and leakage. Macugen was approved for marketing in the United States in December 2004.